As BRCA1-mutated tumors may be more sensitive to treatments with platinum derivatives and benefit from treatment with inhibitors of PARP, similar strategies could also be hypothesized for BC patients harboring ATM gene mutations [63]. This evidence concerns the gene ATM and breast cancer.